See more : Nichiryoku Co.,Ltd. (7578.T) Income Statement Analysis – Financial Results
Complete financial analysis of Advaxis, Inc. (ADXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advaxis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Baazeem Trading Company (4051.SR) Income Statement Analysis – Financial Results
- Rural Funds Group (RFF.AX) Income Statement Analysis – Financial Results
- JMJ Fintech Limited (JMJFIN.BO) Income Statement Analysis – Financial Results
- Sterling Bancorp (STL) Income Statement Analysis – Financial Results
- Better World Acquisition Corp. (BWAC) Income Statement Analysis – Financial Results
Advaxis, Inc. (ADXS)
About Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.00K | 250.00K | 3.24M | 253.00K | 2.33M | 6.06M | 12.03M | 3.99M | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Cost of Revenue | 13.00K | 314.00K | 3.71M | 1.29M | 1.29M | 0.00 | 0.00 | 0.00 | 265.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -64.00K | -468.00K | -1.03M | 1.05M | 6.06M | 12.03M | 3.99M | -265.39K | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -25.60% | -14.44% | -407.91% | 44.94% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.08M | 7.61M | 10.56M | 15.61M | 14.42M | 56.97M | 71.90M | 48.77M | 24.22M | 8.69M | 5.62M | 6.65M | 8.08M | 4.90M | 2.32M | 2.48M | 2.13M | 1.40M | 1.18M | 125.94K | 0.00 | 0.00 |
| General & Administrative | 12.19M | 9.74M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Selling & Marketing | 0.00 | -473.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.19M | 8.42M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Other Expenses | 0.00 | 3.05M | -1.00K | -3.00K | 0.00 | -63.00K | -123.00 | -201.00 | -35.08K | 6.24K | -3.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.27M | 16.03M | 22.03M | 26.70M | 18.76M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Cost & Expenses | 36.28M | 16.34M | 22.03M | 26.70M | 20.05M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Interest Income | 28.00K | 74.00K | 5.00K | 110.00K | 225.00K | 577.00K | 669.76K | 331.53K | 114.22K | 36.31K | 5.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.75M | 0.00 | 260.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.25K | 987.75K | 4.54M | 4.70M | 3.81M | 851.01K | 0.00 | 0.00 | 0.00 | 36.67K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 369.00K | 314.00K | 990.00K | 1.98M | 1.48M | 1.50M | 1.12M | 536.19K | 265.39K | 203.30K | 178.64K | 161.78K | 160.69K | 138.95K | 111.16K | 197.35K | 263.78K | 144.39K | 41.10K | 15.82K | 0.00 | 0.00 |
| EBITDA | -35.87M | -15.78M | -18.77M | -24.39M | -17.56M | -72.28M | -97.43M | -76.03M | -48.36M | -19.29M | -18.04M | -12.17M | -13.78M | -7.79M | -4.88M | -5.30M | -7.09M | -193.70K | -1.80M | -518.14K | -10.00K | -10.00K |
| EBITDA Ratio | -275,915.38% | -6,310.40% | -579.20% | -9,641.90% | -752.40% | -1,192.12% | -809.80% | -1,903.07% | 0.00% | -1,929.27% | 0.00% | 0.00% | 0.00% | -1,531.44% | -16,422.51% | -8,064.18% | -4,601.10% | -44.84% | -325.82% | -445.12% | 0.00% | 0.00% |
| Operating Income | -36.27M | -16.09M | -18.79M | -26.45M | -17.71M | -70.38M | -98.53M | -76.49M | -48.67M | -19.54M | -14.69M | -12.33M | -13.02M | -7.93M | -4.99M | -5.45M | -4.60M | -3.05M | -1.84M | -533.90K | -10.00K | -10.00K |
| Operating Income Ratio | -278,969.23% | -6,436.00% | -579.81% | -10,454.15% | -758.83% | -1,160.79% | -818.95% | -1,914.77% | 0.00% | -1,953.86% | 0.00% | 0.00% | 0.00% | -1,558.76% | -16,796.90% | -8,293.45% | -2,985.06% | -705.91% | -333.25% | -458.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.72M | 1.78M | 974.00K | 30.00K | 225.00K | 3.91M | 20.03K | 68.85K | -84.03K | 625.33K | -5.03M | 4.45M | 10.15M | 649.70K | 5.85M | 46.63K | 2.76M | -2.71M | 36.67K | 57.00 | 0.00 | 0.00 |
| Income Before Tax | -51.98M | -14.31M | -17.81M | -26.42M | -17.49M | -66.47M | -97.84M | -76.09M | -48.64M | -18.88M | -20.71M | -12.42M | -8.50M | -11.09M | 7.22K | -5.41M | -1.85M | -5.76M | -1.81M | -533.85K | -10.00K | -10.00K |
| Income Before Tax Ratio | -399,876.92% | -5,723.60% | -549.75% | -10,442.29% | -749.19% | -1,096.24% | -813.21% | -1,904.75% | 0.00% | -1,888.22% | 0.00% | 0.00% | 0.00% | -2,181.24% | 24.32% | -8,222.52% | -1,197.96% | -1,333.56% | -326.62% | -458.61% | 0.00% | 0.00% |
| Income Tax Expense | -3.91M | 50.00K | 50.00K | 50.00K | 306.00K | 50.00K | -4.40M | -2.54M | -1.61M | -2.36M | -725.19K | -346.79K | -379.47K | -278.98K | -922.02K | -35.37K | -2.15M | 3.15M | -36.67K | 4.17K | 0.00 | 0.00 |
| Net Income | -48.07M | -14.36M | -17.86M | -26.47M | -17.79M | -66.52M | -93.44M | -73.56M | -47.03M | -16.53M | -19.99M | -12.07M | -8.12M | -10.81M | 929.24K | -5.42M | -2.45M | -6.20M | -1.81M | -538.08K | -10.00K | -10.00K |
| Net Income Ratio | -369,784.62% | -5,743.60% | -551.30% | -10,462.06% | -762.30% | -1,097.06% | -776.62% | -1,841.27% | 0.00% | -1,652.53% | 0.00% | 0.00% | 0.00% | -2,126.37% | 3,129.82% | -8,239.65% | -1,591.72% | -1,434.79% | -326.62% | -462.24% | 0.00% | 0.00% |
| EPS | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| EPS Diluted | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
| Weighted Avg Shares Out (Dil) | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting approval...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Advaxis, Inc.- ADXS
New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/advaxis-inc-information-request-formor contact Joseph E. Levi,...
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of...
Here is What Hedge Funds Think About Advaxis, Inc. (ADXS)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought...
Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common...
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®
Telefonaktiebolaget LM Ericsson (publ) (NASDAQ:ERIC) Short Interest Update
Telefonaktiebolaget LM Ericsson (publ) (NASDAQ:ERIC) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 10,610,000 shares, an increase of 33.6% from the September 15th total of 7,940,000 shares....
Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) Lowered to “Strong Sell” at BidaskClub
Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, BidAskClub reports. Other analysts have also recently issued research...
LM Funding America (NASDAQ:LMFA) Shares Gap Down to $0.87
LM Funding America Inc (NASDAQ:LMFA) gapped down before the market opened on Wednesday . The stock had previously closed at $0.87, but opened at $0.74. LM Funding America shares last traded at $0.73, with a volume of 154,634 shares trading...
25,137 Shares in Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) Purchased by Engineers Gate Manager LP
Engineers Gate Manager LP acquired a new position in shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,137...
Source: https://incomestatements.info
Category: Stock Reports